Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study

The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical complications. This study aimed to examine the clinical predictors, outcomes, a...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Chloe Ahryung Lim, Sunita Ghosh, Hali Morrison, Daniel Meyers, Igor Stukalin, Marc Kerba, Desiree Hao, Aliyah Pabani
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Subjects:	durvalumab-associated pneumonitis immunotherapy toxicity radiation pneumonitis
Online Access:	https://www.mdpi.com/1718-7729/30/12/757

Similar Items

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
by: Masahiro Torasawa, et al.
Published: (2023-10-01)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
by: Narek Shaverdian, MD, et al.
Published: (2021-07-01)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
by: Yoshiko Oshiro, et al.
Published: (2021-07-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review
by: Kerri McGovern, et al.
Published: (2019-06-01)

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer
by: Zhang A, et al.
Published: (2022-08-01)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
by: Beatrice T. B. Preti, et al.
Published: (2023-08-01)

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
by: Anthony M. Brade, et al.
Published: (2024-10-01)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
by: Yu Miura, et al.
Published: (2020-05-01)

Predictive value of machine learning for radiation pneumonitis and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis
by: Shenghan Wang, et al.
Published: (2025-07-01)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
by: Xiaotong Lu, et al.
Published: (2022-06-01)

Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01)

Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy
by: Yechen Ma, et al.
Published: (2025-04-01)

A case of pneumomediastinum complicating immunotherapy associated pneumonitis
by: Anthony Carrozzi, et al.
Published: (2024-06-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01)

Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer
by: Mai Sakagami, et al.
Published: (2023-05-01)

Methotrexate induced pneumonitis – A case report and review of literature
by: V Vinay, et al.
Published: (2022-01-01)

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review
by: Luke Ardolino, et al.
Published: (2021-06-01)

A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature
by: Ying Dai, et al.
Published: (2021-02-01)

Enrichment of prevotella melaninogenica in the lower respiratory tract links to checkpoint inhibitor pneumonitis and radiation pneumonitis
by: Jiajun Chen, et al.
Published: (2025-10-01)

Immunotherapy enhances the risk of tumor oxidative stress and metastasis in lung cancer with radiation pneumonitis
by: Ruidi Jiao, et al.
Published: (2025-07-01)

Early recognition of acute pneumonitis in amiodarone treatment
by: Rishi Vinod Lohiya, et al.
Published: (2018-01-01)

Multidisciplinary Discussion for Fibrotic Hypersensitivity Pneumonitis with a Positive Antigen Avoidance
by: Okuda R, et al.
Published: (2023-05-01)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
by: Leslie E. Kao, et al.
Published: (2023-10-01)

Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event
by: Evan Bryson, et al.
Published: (2020-12-01)

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
by: Feihu Chen, et al.
Published: (2023-06-01)

Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer
by: Qingtao Qiu, et al.
Published: (2022-04-01)

Volumetric Estimation of Lung Dose and Its Association with Pneumonitis Following Radiotherapy in Breast Cancer Patients
by: Geetha Muttath, et al.
Published: (2022-04-01)

Pneumonitis as a complication of Immunotherapy of oncological diseases: difficulties in diagnosis and treatment
by: Yuliia S. Chizhova, et al.
Published: (2025-01-01)

Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis
by: Michelle Ploch, et al.
Published: (2025-01-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report
by: M.E. Kuipers, et al.
Published: (2024-07-01)

Research Progress of Macrophages in Development of Radiation Pneumonitis and Pulmonary Fibrosis
by: XU Yaping, et al.
Published: (2023-07-01)

Radiation pneumonitis prediction with dual-radiomics for esophageal cancer underwent radiotherapy
by: Chenyu Li, et al.
Published: (2024-06-01)

Successful Management of Steroid‐Refractory Immune‐Related Pneumonitis With Mycophenolate Mofetil: A Case Report
by: Hiroaki Ota, et al.
Published: (2025-04-01)

Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy
by: Jeffrey M. Ryckman, et al.
Published: (2020-02-01)

Fulminant lupus pneumonitis complicating systemic lupus erythematosus in the elderly
by: Wiem Helali, et al.
Published: (2023-02-01)

Recrudescence of Natalizumab‐Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review
by: Gerardo Arwi, et al.
Published: (2025-04-01)